T1	Pharmacodynamic_phenotype	26 67	growth suppressive effects of doxorubicin
T2	Pharmacodynamic_phenotype	70 81	oxaliplatin
T3	Disease	112 135	stomach carcinoma cells
T4	Phenotype	159 172	BCL2L12 , BAX
T5	Phenotype	173 178	, and
T6	Phenotype	183 211	2 expression profiles in the
T7	Phenotype	212 268	molecular signaling pathways triggered by chemotherapy .
R1	influences	Arg1:T1	Arg2:T2
R2	treats	Arg1:T1	Arg2:T3
R3	influences	Arg1:T1	Arg2:T5
R4	influences	Arg1:T1	Arg2:T6
R5	influences	Arg1:T1	Arg2:T7
R6	influences	Arg1:T2	Arg2:T1
R7	treats	Arg1:T2	Arg2:T3
R8	influences	Arg1:T2	Arg2:T7
R9	isAssociatedWith	Arg1:T3	Arg2:T1
R10	isAssociatedWith	Arg1:T3	Arg2:T2
R11	isAssociatedWith	Arg1:T3	Arg2:T4
R12	isAssociatedWith	Arg1:T3	Arg2:T5
R13	isAssociatedWith	Arg1:T3	Arg2:T6
R14	influences	Arg1:T3	Arg2:T7
R15	influences	Arg1:T4	Arg2:T1
R16	influences	Arg1:T4	Arg2:T2
R17	influences	Arg1:T4	Arg2:T3
R18	influences	Arg1:T4	Arg2:T5
R19	influences	Arg1:T4	Arg2:T6
R20	influences	Arg1:T4	Arg2:T7
R21	influences	Arg1:T5	Arg2:T1
R22	influences	Arg1:T5	Arg2:T2
R23	influences	Arg1:T5	Arg2:T3
R24	influences	Arg1:T5	Arg2:T4
R25	influences	Arg1:T5	Arg2:T6
R26	influences	Arg1:T5	Arg2:T7
R27	influences	Arg1:T6	Arg2:T1
R28	influences	Arg1:T6	Arg2:T2
R29	influences	Arg1:T6	Arg2:T3
R30	influences	Arg1:T6	Arg2:T4
R31	influences	Arg1:T6	Arg2:T5
R32	influences	Arg1:T6	Arg2:T7
R33	influences	Arg1:T7	Arg2:T1
R34	influences	Arg1:T7	Arg2:T2
R35	influences	Arg1:T7	Arg2:T4
R36	influences	Arg1:T7	Arg2:T5
R37	influences	Arg1:T7	Arg2:T6
